Risk of nephrogenic systemic fibrosis in liver transplantation patients

American Journal of Roentgenology

Volumn 197, Issue 3, 2011, Pages 658-662

  Chow, Daniel S ^a,b   Bahrami, Simin ^a   Raman, Steven S ^a   Rotchel, Sepehr ^c   Sayre, James W ^a   Busuttil, Ronald W ^a   Lu, David S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contrast agents; Gadolinium; Liver transplantation; MRI; Nephrogenic systemic fibrosis

Indexed keywords

GADODIAMIDE; GADOLINIUM PENTETATE;

ADULT; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; DISEASE CLASSIFICATION; FEMALE; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR;

CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; INCIDENCE; KIDNEY FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEPHROGENIC FIBROSING DERMOPATHY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 80052257769     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.5976     Document Type: Article

References (25)

1. Cowper SE. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005; 46:763-765 (Pubitemid 41383957)
2. Galan A, Cowper S, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing demopathy). Curr Opin Rheumatol 2006; 18:614-617 (Pubitemid 44607415)
3. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003; 139:903-906 (Pubitemid 36898926)
4. Cowper SE. Nephrogenic fibrosing dermopathy. International Center for Nephrogenic Systemic Fibrosis Research (ICNSFR) Website. www.icnfdr. org. Accessed July 19, 2009
5. Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21:1104-1108
6. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362 (Pubitemid 44300951)
7. U.S. Food and Drug Administration Website. Information for healthcare professionals: gadolinium- based contrast agents for magnetic resonance imaging scans (marketed as Omniscan, Opti- MARK, Magnevist, ProHance, and MultiHance). www.fda.gov/Drugs/DrugSafety/Postmarket- DrugSafetyInformationforPatientsandProviders/ ucm142905.htm. Updated December 22, 2006. Accessed July 19, 2009
8. Perez-Rodriguez J, Lai S, Ehst B, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment- report of 33 cases. Radiology 2009; 250:371-377
9. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008; 66:230-234
10. Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006; 6:2212-2217 (Pubitemid 44199558)
11. Chiu H, Wells G, Carag H, Canova E, Firpi RJ. Nephrogenic fibrosing dermopathy: a rare entity in patients awaiting liver transplantation. Liver Transpl 2004; 10:465-466 (Pubitemid 38380326)
12. U.S. Food and Drug Administration Website. Information for healthcare professionals: gadoliniumbased contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm142884.htm. Updated May 23, 2007. Accessed July 19, 2009
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation-Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470 (Pubitemid 29135798)
14. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 1976: 259-263
15. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008; 248:807-816
16. Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009; 30:1313-1322
17. Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN. Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radio- Graphics 2009; 29:1565-1574
18. Bryant BJ 2nd, Im K, Broome DR. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clin Radiol 2009; 64:706-713
19. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148-157 (Pubitemid 46579705)
20. Idée JM, Port M, Dencausse A, Lancelot E, Corot C. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009; 47:855-869
21. Tombach B, Bremer C, Reimer P, et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol 2000; 35:35-40 (Pubitemid 30033605)
22. Hasebroock KM, Serkova NJ. Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol 2009; 5:403-416
23. Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 2003; 41:269-278 (Pubitemid 36152445)
24. Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging 2009; 30:1298-1308
25. Leiner T, Kucharczyk W. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe. J Magn Reson Imaging 2009; 30:1357-1363